Literature DB >> 30321624

An integrated program of extracorporeal membrane oxygenation (ECMO) assisted cardiopulmonary resuscitation and uncontrolled donation after circulatory determination of death in refractory cardiac arrest.

Roberto Roncon-Albuquerque1, Sérgio Gaião2, Paulo Figueiredo3, Nuno Príncipe4, Carla Basílio4, Paulo Mergulhão2, Sofia Silva4, Teresa Honrado4, Francisco Cruz5, Manuel Pestana6, Gerardo Oliveira7, Luis Meira8, Ana França9, João Paulo Almeida-Sousa9, Fernando Araújo10, José-Artur Paiva2.   

Abstract

AIM: To assess the feasibility of an integrated program of extracorporeal cardiopulmonary resuscitation (ECPR) and uncontrolled donation after circulatory determination of death (uDCDD) in refractory cardiac arrest (rCA).
METHODS: Single center, prospective, observational study of selected patients with in-hospital (IHCA) and out-of-hospital (OHCA) rCA occurring in an urban area of ∼1.5 million inhabitants, between October-2016 and May-2018. 65 year old or younger patients without significant bleeding or comorbidities with witnessed nonasystolic cardiac arrests were triaged to ECPR if they had a reversible cause and high quality CPR lasting < 60 min. Otherwise they were considered for uDCDD after a ten minute no touch period using normothermic regional perfusion.
RESULTS: 58 patients were included, of which 41 (71%) were OHCA and 18 (31%) had ECPR initiated. Median age was 52 (IQR 45-56) years. Cannulation was successful in 49/58 (84%) cases. Compared to ECPR, patients referred for uDCDD were more frequently OHCA (90 vs. 28%), had bystander CPR (28 vs. 83%) and prolonged low-flow period (40 (35-50) vs. 60 (49-78) min). Survival to hospital discharge with full neurological recovery (cerebral performance category 1) occurred in 6/18 (33%) ECPR patients. uDCDD resulted in transplantation of 44 kidneys.
CONCLUSIONS: An integrated program for rCA consisting of a formal pathway to uDCDD referral in ECPR ineligible patients is feasible. ECPR-referred patients had a reasonable survival with full neurologic recovery. Successful kidney transplantation was achieved with uDCDD.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ECMO assisted cardiopulmonary resuscitation; Extracorporeal membrane oxygenation (ECMO); Refractory cardiac arrest; Uncontrolled donation after circulatory determination of death (uDCDD)

Mesh:

Year:  2018        PMID: 30321624     DOI: 10.1016/j.resuscitation.2018.10.016

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  5 in total

Review 1.  Organ donation after circulatory death: current status and future potential.

Authors:  Martin Smith; B Dominguez-Gil; D M Greer; A R Manara; M J Souter
Journal:  Intensive Care Med       Date:  2019-02-06       Impact factor: 17.440

2.  Partially revived pig organs could force a rethink of critical-care processes.

Authors:  Brendan Parent
Journal:  Nature       Date:  2022-08       Impact factor: 69.504

Review 3.  Understanding the Adverse Hemodynamic Effects of Serious Thoracic Injuries During Cardiopulmonary Resuscitation: A Review and Approach Based on the Campbell Diagram.

Authors:  Youcef Azeli; Juan Víctor Lorente Olazabal; Manuel Ignacio Monge García; Alfredo Bardají
Journal:  Front Physiol       Date:  2019-12-03       Impact factor: 4.566

4.  Kidney Transplants From Donors on Extracorporeal Membrane Oxygenation Prior to Death Are Associated With Better Long-Term Renal Function Compared to Donors After Circulatory Death.

Authors:  Marilena Gregorini; Elena Ticozzelli; Massimo Abelli; Maria A Grignano; Eleonora F Pattonieri; Alessandro Giacomoni; Luciano De Carlis; Antonio Dell'Acqua; Rossana Caldara; Carlo Socci; Andrea Bottazzi; Carmelo Libetta; Vincenzo Sepe; Stefano Malabarba; Federica Manzoni; Catherine Klersy; Giuseppe Piccolo; Teresa Rampino
Journal:  Transpl Int       Date:  2022-02-08       Impact factor: 3.782

5.  Uncontrolled donation after circulatory death and SARS-CoV2 pandemia: still feasible?

Authors:  Chiara Lazzeri; Manuela Bonizzoli; Adriano Peris
Journal:  Eur J Emerg Med       Date:  2022-03-29       Impact factor: 4.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.